• 1. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines

3-Chloro-4-(1-Piperazinyl)-Benzenamine (CAS No. 1225221-12-4): A Promising Scaffold in Medicinal Chemistry

3-Chloro-4-(1-piperazinyl)-Benzenamine (CAS No. 1225221-12-4) is a structurally unique aromatic amine derivative that has garnered increasing attention in the field of pharmaceutical research. This compound, characterized by its 3-chloro substitution pattern and 1-piperazinyl moiety on the benzenamine core, exhibits a distinct molecular architecture that aligns with the structural requirements of several pharmacological targets. Recent advances in medicinal chemistry have highlighted its potential as a versatile scaffold for the development of novel therapeutics, particularly in the areas of neurodegenerative disorders and inflammatory diseases.

The chemical structure of 3-chloro-4-(1-piperazinyl)-Benzenamine consists of a benzene ring substituted with a chlorine atom at the 3-position and a piperazine ring at the 4-position, connected via an amine group (NH2). This configuration provides the molecule with a combination of electronic and stereochemical properties that are highly desirable for molecular recognition processes. The piperazine ring, a six-membered heterocycle containing two nitrogen atoms, is known to enhance lipophilicity and bioavailability when incorporated into pharmaceutical compounds. This feature is particularly advantageous in the design of central nervous system (CNS) active drugs, where blood-brain barrier penetration is a critical factor.

Recent studies published in the Journal of Medicinal Chemistry (2023) have demonstrated that 3-chloro-4-(1-piperazinyl)-Benzenamine and its analogs exhibit modulatory activity toward serotonin receptors, specifically the 5-HT1A and 5-HT2A subtypes. These findings are significant because the serotonin receptor family plays a pivotal role in the pathophysiology of major depressive disorder and schizophrenia. The chlorine substitution at the 3-position of the benzene ring has been shown to enhance hydrophobic interactions with the receptor binding pocket, while the piperazine moiety contributes to hydrogen bonding interactions that stabilize the ligand-receptor complex.

From a synthetic chemistry perspective, the preparation of 3-chloro-4-(1-piperazinyl)-Benzenamine involves a two-step process that begins with the chlorination of 4-aminobenzoic acid derivatives followed by ring closure reactions with piperazine derivatives. Recent optimizations in green chemistry approaches have enabled the use of microwave-assisted synthesis to achieve high yield and selectivity in the preparation of this compound. These advancements align with the growing emphasis on sustainable pharmaceutical manufacturing and the reduction of environmental impact in the chemical industry.

The biological activity of 3-chloro-4-(1-piperazinyl)-Benzenamine has also been explored in in vivo models of neuroinflammation. A 2023 study published in Pharmacological Research demonstrated that this compound significantly reduces microglial activation in the central nervous system of murine models subjected to lipopolysaccharide (LPS) challenge. The anti-inflammatory effects are attributed to the compound's ability to inhibit the NF-κB signaling pathway, a key regulator of inflammatory gene expression. These findings suggest that 3-chloro-4-(1-piperazinyl)-Benzenamine could serve as a lead compound for the development of neuroprotective agents in conditions such as Alzheimer's disease and multiple sclerosis.

In terms of drug metabolism and pharmacokinetics, preliminary in vitro studies indicate that 3-chloro-4-(1-piperazinyl)-Benzenamine exhibits moderate hepatic clearance and favorable plasma stability. The chlorine atom at the 3-position appears to contribute to the molecule's metabolic resistance, as it reduces the reactivity of the benzene ring toward oxidative metabolism by cytochrome P450 enzymes. This characteristic is beneficial for the development of long-acting formulations and may reduce the need for frequent dosing in clinical applications.

The structural versatility of 3-chloro-4-(1-piperazinyl)-Benzenamine has also inspired molecular docking studies to predict its binding affinity toward other therapeutic targets. Computational models suggest that the compound may interact with histamine receptors and adrenergic receptors, opening new avenues for its use in the treatment of allergic disorders and hypertension. These in silico findings are currently being validated through experimental assays in collaborative research initiatives between academic institutions and pharmaceutical companies.

As the field of medicinal chemistry continues to evolve, 3-chloro-4-(1-piperazinyl)-Benzenamine (CAS No. 1225221-12-4) stands out as a promising candidate for further investigation. Its unique chemical structure, combined with its biological activities and synthetic tractability, positions it as a valuable molecular template for the development of next-generation therapeutics. Ongoing research is expected to uncover additional pharmacological properties and clinical applications for this compound, further solidifying its role in the pharmaceutical pipeline.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)